Skip to main content
rss feedemail usour twitterour facebook page linkdin youtubeinstagram
Tuesday, February 08 2022

4TH Global Sickle Cell Disease Congress in Paris, France.

ESCF participates in the 4th Global Sickle Cell Disease congress in Paris, France organised by the Global Sickle Cell Disease Network-GSCDN.
The federation successfully held a patient perspective session during the conference on the 18th of June and highlighted major expectations from patients in Europe and around the globe on treatments, management and policy for Sickle cell disease.

The gathering was an opportunity for the ESCF Board to hold its first in person board and patient meeting since the organisation’s official establishment in June 2020.


Posted by: ESCF Admin AT 01:10 am   |  Permalink   |  Email
Saturday, February 05 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Pharmaceuticals Newsroom (

31 patients with severe Sickle Cell Disease characterized by recurrent vaso-occlusive crises (VOCs) (mean of 3.9 VOCs per year over the prior two years) were free of excruciating pain episodes after an exa-cel infusion through duration of follow-up, with follow-up ranging from 2.0 to 32.3 months.


Posted by: ESCF Admin AT 03:02 pm   |  Permalink   |  Email